Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29074595

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2017 Oct 26
First author
Harrison CN

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2017 Oct 26;130(17):1873-1874. doi: 10.1182/blood-2017-08-802165.
    note
    Source null
    related pmid
    29074591
    relationship
    Comment in

Authors and identifiers

  1. name
    Harrison CN
    type
    Author
  2. name
    Mead AJ
    type
    Author
  3. name
    Panchal A
    type
    Author
  4. name
    Fox S
    type
    Author
  5. name
    Yap C
    type
    Author
  6. name
    Gbandi E
    type
    Author
  7. name
    Houlton A
    type
    Author
  8. name
    Alimam S
    type
    Author
  9. name
    Ewing J
    type
    Author
  10. name
    Wood M
    type
    Author
  11. name
    Chen F
    type
    Author
  12. name
    Coppell J
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Harrison CN
    type
    Author
  2. name
    Mead AJ
    type
    Author
  3. name
    Panchal A
    type
    Author
  4. name
    Fox S
    type
    Author
  5. name
    Yap C
    type
    Author
  6. name
    Gbandi E
    type
    Author
  7. name
    Houlton A
    type
    Author
  8. name
    Alimam S
    type
    Author
  9. name
    Ewing J
    type
    Author
  10. name
    Wood M
    type
    Author
  11. name
    Chen F
    type
    Author
  12. name
    Coppell J
    type
    Author
bibliography ids
  1. nci-bib-9387d0b59ac474f117a98650
book metadata
content sha256
86578449bfa577b867a5fde64a39032f04a0cd2ffe21ad29b0945edc329aa31a
document type
citation
dois
  1. 10.1182/blood-2017-05-785790
electronic publication date
display
2017 Aug 9
precision
day
year
2017
evidence scope
bibliographic_metadata_only
id
pubmed:29074595
immutable id
pubmed:29074595@86578449bfa577b867a5fde64a39032f04a0cd2ffe21ad29b0945edc329aa31a
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
17
name
Blood
nlm unique id
7603509
pages
1889-1897
volume
130
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2017 Oct 26;130(17):1873-1874. doi: 10.1182/blood-2017-08-802165.
    note
    Source null
    related pmid
    29074591
    relationship
    Comment in
outcomes validated
false
pmid
29074595
provenance
batch id
fb25b16edcb1373b70c1
provider
NCBI PubMed ESummary
record sha256
28eaccf688a429a19cf64a8c00b60d72f73fd1525bae1c671e8b13e54118de93
response sha256
182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
retrieved at
2026-09-09T23:47:28.490065+00:00
publication date
display
2017 Oct 26
precision
day
year
2017
publication types
  1. Comparative Study
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/29074595/
title
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.

Preserved source evidence · Not medical advice